Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of CS1003 in Subjects With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03475251
Recruitment Status : Recruiting
First Posted : March 23, 2018
Last Update Posted : July 17, 2018
Sponsor:
Information provided by (Responsible Party):
CStone Pharmaceuticals

Brief Summary:
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as CS1003 in patients with advanced tumors.

Condition or disease Intervention/treatment Phase
Advanced Cancer Biological: CS1003 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors
Actual Study Start Date : May 9, 2018
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2021

Arm Intervention/treatment
Experimental: CS1003 Biological: CS1003
In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.




Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: From the day of first dose to 30 days after last dose of CS1003 ]

Secondary Outcome Measures :
  1. Area under the plasma concentration-time curve (AUC) [ Time Frame: From the day of first dose to 30 days after last dose of CS1003 ]
  2. Maximum plasma concentration (Cmax) [ Time Frame: From the day of first dose to 30 days after last dose of CS1003 ]
  3. Time to reach maximum plasma concentration (Tmax) [ Time Frame: From the day of first dose to 30 days after last dose of CS1003 ]
  4. Terminal elimination half-life (t1/2) [ Time Frame: From the day of first dose to 30 days after last dose of CS1003 ]
  5. Disease assessment by CT/MRI scan [ Time Frame: To be performed every 9 weeks during treatment period (up to 2 years) and within 30 days after last dose of CS1003 ]
  6. Anti-CS1003 antibody [ Time Frame: From the day of first dose to 30 days after last dose of CS1003 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects must have histologically or cytologically confirmed advanced or metastatic solid tumor and have progressed, are intolerant to, refuse to accept or do not have access to standard therapy.
  2. ECOG performance status of 0 or 1.
  3. Subjects with evaluable but non-measurable lesion are eligible for Phase Ia. Subjects must have at least one measurable lesion per RECIST Version 1.1 to be eligible for Phase Ib.
  4. Archived tumor tissue samples need to be collected, or subjects consent to undergo pre-treatment biopsy if archived sample is not available.
  5. Life expectancy ≥ 3 months.
  6. Subject must have adequate organ function.
  7. Use of effective contraception (males and females).

Exclusion Criteria:

  1. Subjects with known symptomatic or untreated brain metastasis or other CNS metastasis.
  2. Subjects with active autoimmune diseases or history of autoimmune diseases.
  3. Subjects who have to receive glucocorticoids (prednisone at > 10 mg/day or equivalent) or other immunosuppression within 14 days prior to the first dose of CS1003.
  4. Subjects with other malignant tumor(s) in the past 2 years are not eligible for Phase Ib, except for those with basal cell carcinoma, in situ breast cancer and cervical carcinoma in situ who have undergone radical treatment.
  5. Subjects who have received any immune checkpoint treatment, including PD-1, PD-L1, etc.
  6. Receipt of chemotherapy, targeted therapy, or any other anti-cancer systemic treatment within 2 weeks prior to the first dose of CS1003.
  7. Receipt of major surgical procedure or wide field of radiation within 28 days prior to the first dose of CS1003, local radiotherapy within 14 days prior to the first dose of CS1003, or radioactive agents within 56 days before the first dose of CS1003.
  8. Receipt of Chinese herbal medicine or Chinese prepared medicine within 7 days prior to the first dose of CS1003.
  9. Receipt of live vaccine within 28 days prior to the first dose of CS1003.
  10. History of interstitial lung disease or non-infectious pneumonitis, except for those induced by radiation therapies.
  11. History of HIV infection.
  12. Subjects with active Hepatitis B and C infection (HBV DNA ≥ 1000 cps/mL or 200 IU/mL) requiring therapy.
  13. Subjects with active infection of tuberculosis.
  14. Subjects with signs or symptoms of any active infection requiring systemic therapy.
  15. History of organ transplantation.
  16. Unresolved toxicities from prior anti-cancer therapy.
  17. History of any irAE of Grade ≥ 3.
  18. History of uncontrolled allergic asthma and serious hypersensitive reaction to monoclonal antibodies.
  19. History of alcoholism or drugs abuse.
  20. Subjects with major cardiovascular diseases.
  21. Any condition that, in the opinion of the investigator or sponsor, would jeopardize compliance.

For more information regarding trial participation, please contact at cstonera@cstonepharma.com


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03475251


Contacts
Layout table for location contacts
Contact: Wendie Yuan +86 21 6109 7678 cstonera@cstonepharma.com

Locations
Layout table for location information
Australia, New South Wales
Scientia Clinical Research Ltd Recruiting
Randwick, New South Wales, Australia, 2031
Sponsors and Collaborators
CStone Pharmaceuticals

Layout table for additonal information
Responsible Party: CStone Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03475251     History of Changes
Other Study ID Numbers: CS1003-101
ACTRN12618000382279 ( Registry Identifier: The Australian New Zealand Clinical Trials Registry )
First Posted: March 23, 2018    Key Record Dates
Last Update Posted: July 17, 2018
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No